[From cardiovascular risk to chronic heart failure].

Suppr

超能文献

作者信息

Ertl Georg

机构信息

Medizinische Universitätsklinik Würzburg.

出版信息

Med Klin (Munich). 2003 Oct 15;98 Suppl 1:17.

PMID:14694837

Abstract

摘要

相似文献

[From cardiovascular risk to chronic heart failure].

Med Klin (Munich). 2003 Oct 15;98 Suppl 1:17.

Heart failure in the diabetic patient.

Cardiol Clin. 2007 Nov;25(4):523-38; vi. doi: 10.1016/j.ccl.2007.08.003.

Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.

Med Hypotheses. 2005;65(1):152-4. doi: 10.1016/j.mehy.2004.12.008. Epub 2005 Jan 28.

Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium.

Mol Cell Endocrinol. 2009 Jan 15;297(1-2):112-26. doi: 10.1016/j.mce.2008.11.016. Epub 2008 Nov 21.

Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.

Int J Cardiol. 2006 Feb 8;107(1):11-20. doi: 10.1016/j.ijcard.2005.02.033.

Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation.

Biochem Biophys Res Commun. 2006 Jun 30;345(2):688-93. doi: 10.1016/j.bbrc.2006.04.090. Epub 2006 May 2.

[Late diagnosis. Only after infarct is diabetes detected].

MMW Fortschr Med. 2004 Jan 29;146(5):51.

Controversy over the cardiovascular effects of thiazolidinediones.

Am J Med. 2008 Apr;121(4):e9. doi: 10.1016/j.amjmed.2007.10.035.

Major adverse cardiac event predictors in survivors of myocardial infarction with asymptomatic left ventricular dysfunction or chronic heart failure.

Med Sci Monit. 2009 Jun;15(6):PH40-8.

The endothelium and vascular inflammation in diabetes.

Diab Vasc Dis Res. 2007 Jun;4(2):84-8. doi: 10.3132/dvdr.2007.025.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

[From cardiovascular risk to chronic heart failure].

Med Klin (Munich). 2003 Oct 15;98 Suppl 1:17.

Heart failure in the diabetic patient.

Cardiol Clin. 2007 Nov;25(4):523-38; vi. doi: 10.1016/j.ccl.2007.08.003.

Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.

Med Hypotheses. 2005;65(1):152-4. doi: 10.1016/j.mehy.2004.12.008. Epub 2005 Jan 28.

Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium.

Mol Cell Endocrinol. 2009 Jan 15;297(1-2):112-26. doi: 10.1016/j.mce.2008.11.016. Epub 2008 Nov 21.

Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.

Int J Cardiol. 2006 Feb 8;107(1):11-20. doi: 10.1016/j.ijcard.2005.02.033.

Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation.

Biochem Biophys Res Commun. 2006 Jun 30;345(2):688-93. doi: 10.1016/j.bbrc.2006.04.090. Epub 2006 May 2.

[Late diagnosis. Only after infarct is diabetes detected].

MMW Fortschr Med. 2004 Jan 29;146(5):51.

Controversy over the cardiovascular effects of thiazolidinediones.

Am J Med. 2008 Apr;121(4):e9. doi: 10.1016/j.amjmed.2007.10.035.

Major adverse cardiac event predictors in survivors of myocardial infarction with asymptomatic left ventricular dysfunction or chronic heart failure.

Med Sci Monit. 2009 Jun;15(6):PH40-8.

The endothelium and vascular inflammation in diabetes.

Diab Vasc Dis Res. 2007 Jun;4(2):84-8. doi: 10.3132/dvdr.2007.025.